C12N 2310/32
Of the sugar
Official title: of the sugar
C12N2310/32 (Of the sugar) appears on 4,122 US grants and 7,520 published applications in this corpus.
Search patents in C12N- Granted patents
- 4,122
- Published applications
- 7,520
- Assignees
- 1,412
- Inventors
- 7,105
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 6 | 0 |
| 1994 | 4 | 0 |
| 1995 | 13 | 0 |
| 1996 | 33 | 0 |
| 1997 | 74 | 0 |
| 1998 | 82 | 0 |
| 1999 | 96 | 0 |
| 2000 | 120 | 0 |
| 2001 | 106 | 15 |
| 2002 | 106 | 63 |
| 2003 | 63 | 296 |
| 2004 | 50 | 309 |
| 2005 | 35 | 226 |
| 2006 | 30 | 129 |
| 2007 | 28 | 150 |
| 2008 | 30 | 105 |
| 2009 | 52 | 193 |
| 2010 | 107 | 189 |
| 2011 | 117 | 205 |
| 2012 | 121 | 214 |
| 2013 | 137 | 204 |
| 2014 | 158 | 242 |
| 2015 | 210 | 326 |
| 2016 | 205 | 355 |
| 2017 | 208 | 311 |
| 2018 | 216 | 328 |
| 2019 | 250 | 374 |
| 2020 | 224 | 382 |
| 2021 | 247 | 437 |
| 2022 | 228 | 468 |
| 2023 | 180 | 482 |
| 2024 | 228 | 541 |
| 2025 | 194 | 563 |
| 2026 | 162 | 413 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy6 Oct 2026US 12,753,407 B2Phio Pharmaceuticals Corp.
- OPA1 antisense oligomers for treatment of conditions and diseases6 Oct 2026US 12,753,408 B2Stoke Therapeutics, Inc.
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Antisense oligonucleotides for the treatment of stargardt disease29 Sep 2026US 12,747,440 B2ProQR Therapeutics II B.V.
- Modified guide rnas8 Oct 2026US 2026/0308577 A1Genentech, Inc.
- Reducing intron retention8 Oct 2026US 2026/0308583 A1University of Southampton
- Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)8 Oct 2026US 2026/0308585 A1Alnylam Pharmaceuticals, Inc.
- Sugar Modified Oligonucleotides and Uses Thereof8 Oct 2026US 2026/0308587 A1Ionis Pharmaceuticals, Inc.
- Methods of treatment of chronic kidney disease8 Oct 2026US 2026/0308590 A1AstraZeneca AB
Most cited
By later US patents
- Genetic inhibition by double-stranded RNA1,185US 6,506,559 B1Carnegie Institute of Washington · 2003
- Methods for identifying nucleic acid ligands856US 5,270,163 AUniversity Research Corporation · 1993
- Antisense oligonucleotide modulation of multidrug resistance-associated protein841US 5,801,154 AIsis Pharmaceuticals, Inc. · 1998
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Oligonucleotide therapeutic agent and method of making same726US 5,023,243 AMolecular Biosystems, Inc. · 1991